Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Alx Oncology Holdings (ALXO) Debt to Equity (2019 - 2026)

Alx Oncology Holdings' Debt to Equity history spans 5 years, with the latest figure at $0.05 for Q4 2023.

  • On a quarterly basis, Debt to Equity rose 21.26% to $0.05 in Q4 2023 year-over-year; TTM through Dec 2023 was $0.05, a 21.26% increase, with the full-year FY2023 number at $0.05, up 21.26% from a year prior.
  • Debt to Equity hit $0.05 in Q4 2023 for Alx Oncology Holdings, down from $0.06 in the prior quarter.
  • Over the last five years, Debt to Equity for ALXO hit a ceiling of $0.06 in Q3 2023 and a floor of -$0.08 in Q4 2019.
  • Historically, Debt to Equity has averaged $0.01 across 5 years, with a median of $0.02 in 2020.
  • Biggest five-year swings in Debt to Equity: skyrocketed 402.03% in 2022 and later increased 21.26% in 2023.
  • Tracing ALXO's Debt to Equity over 5 years: stood at -$0.08 in 2019, then skyrocketed by 129.78% to $0.02 in 2020, then plummeted by 63.48% to $0.01 in 2021, then skyrocketed by 402.03% to $0.04 in 2022, then grew by 21.26% to $0.05 in 2023.
  • Business Quant data shows Debt to Equity for ALXO at $0.05 in Q4 2023, $0.06 in Q3 2023, and $0.04 in Q2 2023.